SCHEMBL3306574

SCHEMBL3306574

CC(C)Cc1cc(CNC(=O)CN2CCN(Cc3ccc4c(c3)OCO4)CC2)nn1-c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1G O43497 4/20 0.57
CACNA1H O95180 4/20 0.57
KCNH2 Q12809 4/20 0.57
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA7 P43166 1/20 0.52
CA9 Q16790 1/20 0.52
ALDH1A1 P00352 8/20 0.49
MAPT P10636 3/20 0.49
LMNA P02545 3/20 0.49
TSHR P16473 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
KDM4E B2RXH2 3/20 0.48
TDP1 Q9NUW8 3/20 0.48
POLB P06746 1/20 0.48
KMT2A Q03164 1/20 0.47
HTT P42858 1/20 0.47
HSD17B10 Q99714 1/20 0.46
FAAH O00519 1/20 0.46
GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3298259 0.90 CA1 (0.54) CA1CA2CA7CA9ALDH1A1
SCHEMBL3298103 0.86 ALDH1A1 (0.55) CACNA1GCACNA1HKCNH2ALDH1A1MAPT
SCHEMBL3306921 0.86 KCNH2 (0.61) CACNA1GCACNA1HKCNH2FAAH
SCHEMBL3299252 0.84 KCNH2 (0.61) CACNA1GCACNA1HKCNH2CA1CA2
SCHEMBL3306793 0.84 KCNH2 (0.61) CACNA1GCACNA1HKCNH2L3MBTL1POLB
SCHEMBL3300454 0.83 CACNA1G (0.60) CACNA1GCACNA1HKCNH2CA1CA2
SCHEMBL3301665 0.82 KCNH2 (0.59) CACNA1GCACNA1HKCNH2MAPTPOLB
SCHEMBL3300579 0.81 KCNH2 (0.56) CACNA1GCACNA1HKCNH2
SCHEMBL26131428 0.80 KCNH2 (0.62) CACNA1GCACNA1HKCNH2
SCHEMBL3304244 0.80 MEN1 (0.57) CACNA1GCACNA1HKCNH2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299072-B2 Pyrazolylmethylamine compounds as calcium channel modulators and preparation method thereof KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2012-10-30 US claimed
US-20100094006-A1 NOVEL PYRAZOLYLMETHYLAMINE COMPOUNDS AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2010-04-15 US claimed
US-8299072-B2 Pyrazolylmethylamine compounds as calcium channel modulators and preparation method thereof KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2012-10-30 US disclosed
US-20100094006-A1 NOVEL PYRAZOLYLMETHYLAMINE COMPOUNDS AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100094006-A1 NOVEL PYRAZOLYLMETHYLAMINE COMPOUNDS AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF CACNA1I, CACNA1C, ORAI1 CACNA1G 7/4885CACNA1H 11/4885KCNH2 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.